Latest Quarterly Report
Filed: 2026-04-30
Key Insights
- The filing is dated April 30, 2026 for Q1 2026 (ended March 31, 2026), indicating the company is operating and filing regularly with the SEC for the medical device sector.
- The XBRL metadata shows detailed segment tracking including Product revenue, Software and Other Services segments, with geographic breakdowns (US and Non-US), suggesting diversified revenue streams across multiple business lines.
- The document references dual-class common stock structure (Class A and Class B), multiple warrant types (public and private), and RSU/stock option equity instruments, indicating a complex capital structure typical of post-SPAC merger companies.
- Presence of customer concentration risk disclosures and inventory valuation tracking suggests the company manages customer dependencies and manufacturing operations, which are typical operational risks for early-stage medical device companies.